Novel D3 Dopamine Receptor Agonists to Treat Dyskinesia in Parkinson's Disease
AssigneesUniversity of Medicine and Dentistry New Jersey Medical School, Philadelphia Health & Education Corporation d/b/a Drexel University College of Medicine
InventorsSandhya Kortagere, Eldo V. Kuzhikandahil
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.
Claims14
A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier and at least one
- compound of formula (I):
- wherein in formula (I):
- R1, R2 and R3 are independently selected from the group consisting of H, cyano, hydroxyl, acetamido, halo, alkoxy, nitro, C1-6 alkyl, substituted C1-6 alkyl, heteroalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, aryl-(C1-3)alkyl, substituted aryl-(C1-3)alkyl, carboxy, alkylcarboxy, formyl, alkyl-carbonyl, aryl-carbonyl, and heteroaryl-carbonyl;
- R4 and R5 are independently selected from the group consisting of H, C1-6 alkyl, substituted C1-6 alkyl, heteroalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, aryl-(C1-3)alkyl, and substituted aryl-(C1-3)alkyl;
- and,
- n is 2, 3, 4 or 5;
- or a pharmaceutically acceptable salt thereof.
(canceled)
7-21. (canceled)
A compound of
- formula (I):
- wherein in formula (I):
- R1, R2 and R3 are independently selected from the group consisting of H, cyano, hydroxyl, acetamido, halo, alkoxy, nitro, C1-6 alkyl, substituted C1-6 alkyl, heteroalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, aryl-(C1-3)alkyl, substituted aryl-(C1-3)alkyl, carboxy, alkylcarboxy, formyl, alkyl-carbonyl, aryl-carbonyl, and heteroaryl-carbonyl;
- R4 and R5 are independently selected from the group consisting of H, C1-6 alkyl, substituted C1-6 alkyl, heteroalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, aryl-(C1-3)alkyl, and substituted aryl-(C1-3)alkyl;
- and,
- n is 2, 3, 4 or 5,
- with the proviso that the compound of formula (I) is not 4-(2-chlorophenyl)-butan-2-amine;
- or a pharmaceutically acceptable salt thereof.
(canceled)
A pharmaceutical composition comprising 4-(2-chlorophenyl)-butan-2-amine.
Dependencies are inferred from the claim text.